輔助生殖技術需求飆升 龍頭貝康醫療(2170.HK)未來成長可期
格隆匯9月15日丨最近兩個月,隨着國家放開三孩政策,前來諮詢輔助生殖的患者,較以前都有不同程度的增加。數據顯示,目前我國育齡夫婦的不孕不育率已經攀升至約12%-18%。專家稱,在輔助生殖的各種技術中,目前,最主流的一種“體外受精”方式,也就是大家常説的“試管嬰兒”,我國每年約有30萬名試管嬰兒誕生。
貝康醫療-B(2170.HK)是國內輔助生殖檢測領域的龍頭企業,產品包含了整個生殖週期的三個階段:植入前、產前和產後。全面覆蓋生殖科、婦產科、男科、遺傳科、兒科、胚胎實驗室、精子庫、分子遺傳實驗室等領域,是國內唯一一家產品組合涵蓋整個生殖週期所有關鍵階段的公司。
隨着我國輔助生殖需求上升,市場有望在未來保持高增長態勢,作為輔助生殖檢測龍頭企業的貝康醫療,未來成長值得期待。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.